The U.S. Food and Drug Administration announced a joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting to discuss Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Read more at http://www.fda.gov/AdvisoryCommittees/Calendar/ucm214816.htm.
FDA announces July 22-23 meeting to discuss extended-release and long-acting opioid analgesics
*Online Bonus Content: This has not been peer reviewed. The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
